Status:
RECRUITING
68Ga-MY6349 PET/CT in Solid Tumors
Lead Sponsor:
The First Affiliated Hospital of Xiamen University
Conditions:
Solid Tumor
Trop2
Eligibility:
All Genders
18+ years
Brief Summary
The objective of the study is to construct a noninvasive approach 68Ga-MY6349 PET/CT to detect the Trop-2 expression of tumor lesions in patients with solid tumors and to identify patients benefiting ...
Detailed Description
As a new trophoblast cell-surface antigen 2 (Trop-2) targeting PET radiotracer, 68Ga-MY6349 is promising as an excellent imaging agent applicable to various cancers. In this research, subjects with va...
Eligibility Criteria
Inclusion Criteria:
- adult patients (aged 18 years or older)
- patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report)
- patients who had scheduled both standard-of-care imaging and 68Ga-MY6349 PET/CT scans
- patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee
Exclusion Criteria:
- patients with pregnancy
- the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent
Key Trial Info
Start Date :
December 10 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT07046702
Start Date
December 10 2024
End Date
December 31 2026
Last Update
July 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China, 361000